Successful Stage 1 data showed a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response, and supports expansion "These exciting clinical ...
Impact of high-dose dexamethasone and prolonged infusion time to prevent hypersensitivity reaction related to oxaliplatin in patients with colorectal cancer. Health-related quality of life in patients ...
Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR of almost 17 months Data establishes clear path in indication with no ...
Goblet cell carcinoid (GCC) tumours of the appendix represent a unique and diagnostically challenging subset of neoplasms that manifest with dual characteristics of both neuroendocrine and ...
Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S. With sufficient cash on hand to execute near-term milestones, the Company expects to avoid immediate ...
The incidence of appendiceal adenocarcinoma in the United States more than tripled among those born in 1980 and rose more than fourfold among those born in 1985 compared with a cohort born in 1945, a ...
Reolysin and Tecentriq combination therapy achieved a 29% objective response rate in third-line metastatic squamous cell anal carcinoma, significantly surpassing historical benchmarks. The median ...
SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech (ONCY) ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results